Bigger than they can carry alone: management is reaching outside the company for capability it lacks, because business a
The model's full reasoning — Q3 2018 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management describe that the company is CURRENTLY GOING OUTSIDE ITSELF TO OBTAIN CAPABILITY IT DOES NOT HAVE — bringing in outside manufacturers, suppliers, contractors, licensors, partners, operators, specialists, or acquired capability — BECAUSE the business it has already won or is already serving has outgrown what the company can do on its own? We need to look for evidence in the transcript. The company is Surmodics. They have a deal with Abbott for SurVeil Drug-Coated Balloon. They are supplying the balloon to Abbott, and collaborating on development, clinical trials, regulatory. That is a partnership where Abbott has commercialization rights. But is that "going outside itself to obtain capability it does not have"? Actually, they are providing capability to Abbott, not the other way around. They are the supplier. So that's not reaching outside for capability. They acquired Embolitech's thrombectomy platform technology. That is acquiring capability. But is that because business has outgrown? The acquisition is for a new technology, not because they have too much business. They are adding to pipeline. So that's not about demand exceeding capacity. They mention they are progressing towards commercial agreements with several interested parties for their products. That is about distribution partners, but that's for commercialization, not for capability to serve demand. They talk about R&D expenses, clinical trials, etc. No mention of outsourcing manufacturing or bringing in outside capacity because they have too much business. The question is very specific: "CURRENTLY GOING OUTSIDE ITSELF TO OBTAIN CAPABILITY IT DOES NOT HAVE" because "the business it has already won or is already serving has outgrown what the company can do on its own." That would be like contract manufacturing, additional capacity, etc. There is no such description. The transcript is about financial results, progress on clinical trials, product development, and partnerships. The Abbott deal is a partnership where they supply product, not where they obtain capability. The Embolitech acquisition is for new technology, not for capacity. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
BRBR · Q4 2023 → YESThe question is whether management describes the company currently going outside itself to obtain capability it does not have because the business it has already won has outgrown what it can do on its...
SYM · Q3 2022 → YESThe question is whether management describes the company currently going outside itself to obtain capability it doesn't have because the business it has already won has outgrown what it can do on its ...
AOSL · Q2 2018 → YESThe question is whether management describes the company currently going outside itself to obtain capability it doesn't have because the business it has already won has outgrown what it can do on its ...